APA (7th ed.) Citation

Ouyang, H., Luo, H., Gao, F., Mie, M., Ren, C., Li, J., . . . Huang, J. S. (2024). A phase II clinical evaluation of radiofrequency ablation (RFA) combined with regorafenib and toripalimab in patients with colorectal cancer with liver metastases. Journal of clinical oncology, 42(16_suppl), 3566. https://doi.org/10.1200/JCO.2024.42.16_suppl.3566

Chicago Style (17th ed.) Citation

Ouyang, Hui, Huiyan Luo, Fei Gao, Man Mie, Chao Ren, Ji-Bin Li, Haiyan Fu, and Jin Shan Huang. "A Phase II Clinical Evaluation of Radiofrequency Ablation (RFA) Combined with Regorafenib and Toripalimab in Patients with Colorectal Cancer with Liver Metastases." Journal of Clinical Oncology 42, no. 16_suppl (2024): 3566. https://doi.org/10.1200/JCO.2024.42.16_suppl.3566.

MLA (9th ed.) Citation

Ouyang, Hui, et al. "A Phase II Clinical Evaluation of Radiofrequency Ablation (RFA) Combined with Regorafenib and Toripalimab in Patients with Colorectal Cancer with Liver Metastases." Journal of Clinical Oncology, vol. 42, no. 16_suppl, 2024, p. 3566, https://doi.org/10.1200/JCO.2024.42.16_suppl.3566.